470 related articles for article (PubMed ID: 32392801)
1. Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma.
Napoli S; Scuderi C; Gattuso G; Bella VD; Candido S; Basile MS; Libra M; Falzone L
Cells; 2020 May; 9(5):. PubMed ID: 32392801
[TBL] [Abstract][Full Text] [Related]
2. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
4. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
Chen Y; Peng W; Raffetto JD; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases in human melanoma.
Hofmann UB; Westphal JR; Van Muijen GN; Ruiter DJ
J Invest Dermatol; 2000 Sep; 115(3):337-44. PubMed ID: 10951266
[TBL] [Abstract][Full Text] [Related]
6. Role of matrix metalloproteinases in melanoma cell invasion.
Hofmann UB; Houben R; Bröcker EB; Becker JC
Biochimie; 2005; 87(3-4):307-14. PubMed ID: 15781317
[TBL] [Abstract][Full Text] [Related]
7. Endogenous and synthetic MMP inhibitors in CNS physiopathology.
Baranger K; Rivera S; Liechti FD; Grandgirard D; Bigas J; Seco J; Tarrago T; Leib SL; Khrestchatisky M
Prog Brain Res; 2014; 214():313-51. PubMed ID: 25410364
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells.
Philip S; Bulbule A; Kundu GC
J Biol Chem; 2001 Nov; 276(48):44926-35. PubMed ID: 11564733
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.
Raeeszadeh-Sarmazdeh M; Do LD; Hritz BG
Cells; 2020 May; 9(5):. PubMed ID: 32466129
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
12. The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis.
Thakur V; Bedogni B
Pharmacol Res; 2016 Sep; 111():17-22. PubMed ID: 27221755
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis.
Leppert D; Lindberg RL; Kappos L; Leib SL
Brain Res Brain Res Rev; 2001 Oct; 36(2-3):249-57. PubMed ID: 11690622
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Synthetic Matrix Metalloproteinase Inhibitors by Fluorogenic Substrate Assay.
Lively TJ; Bosco DB; Khamis ZI; Sang QX
Methods Mol Biol; 2016; 1406():161-70. PubMed ID: 26820953
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.
Chaudhary AK; Chaudhary S; Ghosh K; Nadkarni A
Asian Pac J Cancer Prev; 2016; 17(7):3043-51. PubMed ID: 27509927
[TBL] [Abstract][Full Text] [Related]
16. Ischemic-Reperfusion Injury Increases Matrix Metalloproteinases and Tissue Metalloproteinase Inhibitors in Fetal Sheep Brain.
Chen X; Patra A; Sadowska GB; Stonestreet BS
Dev Neurosci; 2018; 40(3):234-245. PubMed ID: 30048980
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
[TBL] [Abstract][Full Text] [Related]
18. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
19. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.
Wang X; Khalil RA
Adv Pharmacol; 2018; 81():241-330. PubMed ID: 29310800
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis.
Pohl M; Sakurai H; Bush KT; Nigam SK
Am J Physiol Renal Physiol; 2000 Nov; 279(5):F891-900. PubMed ID: 11053050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
